SynthesisEndocrine2026
3β-Hydroxysteroid dehydrogenase type-2 deficiency: Our experience and gonadal function-focused systematic review.
Synthesis in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn 3β-Hydroxysteroid dehydrogenase type-2 (3β-HSD2) deficiency, the gonadal phenotypic spectrum and its correlation with genotype are unclear. We describe our center’s experience and perform a systematic review.
methodsRetrospective record review of five 3β-HSD2 deficiency probands from our center, along with per-patient data analysis of reported probands, was conducted to understand the genotype and gonadal phenotype correlation. Probands were subgrouped based on karyotype and residual enzyme activity (REA) of the genetic variant.
resultsOf 128 probands, subgroups were: 46,XY REA ≤ 2% (n = 66), > 2% (n = 21); 46,XX REA ≤ 2% (n = 29), > 2% (n = 12). All 46,XY probands had atypical genitalia; Sinnecker score ≤ 3 (93.1% vs. 88.2%) and cryptorchidism (13.7% vs. 23.5%) were similar between REA ≤ 2% and > 2% groups. 46,XY probands with pubertal data (REA ≤ 2%: 11, > 2%: 3) all had spontaneous puberty (gynecomastia: 3; early puberty: 2) with normal testosterone and gonadotropins (except two). Testicular adrenal rest tumors (TARTs) were reported in seven (median age 13 years); some retained spermatogenesis, and one case documented paternity. No testicular germ-cell tumors were reported. 46,XX probands with pubertal data (REA ≤ 2%: 12, > 2%: 4), all had spontaneous puberty except one (pubertal arrest). Median ages at thelarche (9.0 vs. 9.5 years) and menarche (12 vs. 11.5 years) were comparable between REA groups. Polycystic ovarian morphology (PCOM) was reported in seven, and infertility in one.
conclusionNo clear genotype–gonadal phenotype correlation was observed. Pubertal development and hormone secretion are largely preserved irrespective of REA. TARTs and PCOM are not uncommon. Fertility potential requires further studies.
Indexed as
Identifiers
41920275What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.